Visual P300 and Risk for Psychosis Onset in Youth at Clinical High Risk

IF 10.3 1区医学 Q1 NEUROSCIENCES

Biological Psychiatry Pub Date : 2026-07-15 Epub Date: 2026-02-28 DOI:10.1016/j.biopsych.2026.02.013

Holly K. Hamilton, Brian J. Roach, Spero Nicholas, Renée Dembo, Peter M. Bachman, Aysenil Belger, Ricardo E. Carrión, Erica Duncan, Jason K. Johannesen, Gregory A. Light, Margaret A. Niznikiewicz, Jean Addington, Carrie E. Bearden, Kristin S. Cadenhead, Diana O. Perkins, Elaine F. Walker, Scott W. Woods, Tyrone D. Cannon, Daniel H. Mathalon

{"title":"Visual P300 and Risk for Psychosis Onset in Youth at Clinical High Risk","authors":"Holly K. Hamilton, Brian J. Roach, Spero Nicholas, Renée Dembo, Peter M. Bachman, Aysenil Belger, Ricardo E. Carrión, Erica Duncan, Jason K. Johannesen, Gregory A. Light, Margaret A. Niznikiewicz, Jean Addington, Carrie E. Bearden, Kristin S. Cadenhead, Diana O. Perkins, Elaine F. Walker, Scott W. Woods, Tyrone D. Cannon, Daniel H. Mathalon","doi":"10.1016/j.biopsych.2026.02.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Current clinical criteria are not sufficiently predictive of psychosis onset to inform treatment decision-making among individuals who are at clinical high risk for psychosis (CHR). Identifying biomarkers may improve outcome prediction among CHR individuals and clarify the pathogenesis of psychosis. Using data from the 8-site North American Prodrome Longitudinal Study (NAPLS-2), we examined whether visual P300 event-related potential amplitude, which is reduced in schizophrenia, is affected in CHR individuals and associated with future outcomes.</div></div><div><h3>Methods</h3><div>Five hundred thirty-eight CHR individuals and 230 healthy comparison (HC) participants completed baseline electroencephalography recording during a 3-stimulus visual oddball task. The P3b elicited by infrequent target stimuli and P3a elicited by infrequent nontarget novel stimuli were measured. CHR participants who converted to psychosis (<em>n</em> = 71) were compared with nonconverters who were followed for 24 months (<em>n</em> = 218), whose risk symptoms either persisted (<em>n</em> = 132) or remitted (<em>n</em> = 86) during follow-up.</div></div><div><h3>Results</h3><div>P300 amplitudes were modestly reduced across target (P3b) and novel (P3a) stimuli in CHR individuals compared with HCs (Cohen’s <em>d</em> = 0.14), with greater deficits observed in future CHR-converters than in CHR-nonconverters (<em>d</em> = 0.28) and HCs (<em>d</em> = 0.39). CHR-converters had reduced target P3b compared with CHR-nonconverters (<em>d</em> = 0.32) and HCs (<em>d</em> = 0.41), whereas CHR-nonconverters and HCs did not differ (<em>d</em> = 0.07). Novelty P3a was reduced in CHR-converters compared with HCs (<em>d</em> = 0.37) but not CHR-nonconverters (<em>d</em> = 0.24). Adjusting for symptom severity, greater target P3b deficits predicted earlier psychosis conversion (odds ratio, 0.76 [95% CI, 0.59–0.97], <em>p</em> = .029).</div></div><div><h3>Conclusions</h3><div>Visual target P3b deficits are associated with future psychosis conversion and the imminence of conversion, showing promise as a biomarker of psychosis onset among at-risk individuals.</div></div>","PeriodicalId":8918,"journal":{"name":"Biological Psychiatry","volume":"100 2","pages":"Pages 150-159"},"PeriodicalIF":10.3000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006322326000909","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Current clinical criteria are not sufficiently predictive of psychosis onset to inform treatment decision-making among individuals who are at clinical high risk for psychosis (CHR). Identifying biomarkers may improve outcome prediction among CHR individuals and clarify the pathogenesis of psychosis. Using data from the 8-site North American Prodrome Longitudinal Study (NAPLS-2), we examined whether visual P300 event-related potential amplitude, which is reduced in schizophrenia, is affected in CHR individuals and associated with future outcomes.

Methods

Five hundred thirty-eight CHR individuals and 230 healthy comparison (HC) participants completed baseline electroencephalography recording during a 3-stimulus visual oddball task. The P3b elicited by infrequent target stimuli and P3a elicited by infrequent nontarget novel stimuli were measured. CHR participants who converted to psychosis (n = 71) were compared with nonconverters who were followed for 24 months (n = 218), whose risk symptoms either persisted (n = 132) or remitted (n = 86) during follow-up.

Results

P300 amplitudes were modestly reduced across target (P3b) and novel (P3a) stimuli in CHR individuals compared with HCs (Cohen’s d = 0.14), with greater deficits observed in future CHR-converters than in CHR-nonconverters (d = 0.28) and HCs (d = 0.39). CHR-converters had reduced target P3b compared with CHR-nonconverters (d = 0.32) and HCs (d = 0.41), whereas CHR-nonconverters and HCs did not differ (d = 0.07). Novelty P3a was reduced in CHR-converters compared with HCs (d = 0.37) but not CHR-nonconverters (d = 0.24). Adjusting for symptom severity, greater target P3b deficits predicted earlier psychosis conversion (odds ratio, 0.76 [95% CI, 0.59–0.97], p = .029).

Conclusions

Visual target P3b deficits are associated with future psychosis conversion and the imminence of conversion, showing promise as a biomarker of psychosis onset among at-risk individuals.

查看原文本刊更多论文

视觉P300与临床高危青年精神病发病风险

目前的临床标准不能充分预测精神病的发病，为临床精神病高危人群（CHR）的治疗决策提供信息。识别生物标志物可以改善CHR个体的预后预测，并阐明精神病的发病机制。使用来自北美8点前驱期纵向研究（NAPLS-2）的数据，我们检查了精神分裂症患者视觉P300事件相关电位（ERP）振幅降低是否会影响CHR个体并与未来结果相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biological Psychiatry 医学-精神病学

CiteScore

18.80

自引率

2.80%

发文量

1398

审稿时长

33 days

期刊介绍： Biological Psychiatry is an official journal of the Society of Biological Psychiatry and was established in 1969. It is the first journal in the Biological Psychiatry family, which also includes Biological Psychiatry: Cognitive Neuroscience and Neuroimaging and Biological Psychiatry: Global Open Science. The Society's main goal is to promote excellence in scientific research and education in the fields related to the nature, causes, mechanisms, and treatments of disorders pertaining to thought, emotion, and behavior. To fulfill this mission, Biological Psychiatry publishes peer-reviewed, rapid-publication articles that present new findings from original basic, translational, and clinical mechanistic research, ultimately advancing our understanding of psychiatric disorders and their treatment. The journal also encourages the submission of reviews and commentaries on current research and topics of interest.